Compounds > 1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1h,3h)-pyrimidinedione
Page last updated: 2024-12-11
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1h,3h)-pyrimidinedione
Description
The compound you described, **1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1H,3H)-pyrimidinedione**, is a synthetic analog of the nucleoside **thymidine**.
**Here's a breakdown:**
* **Thymidine** is a fundamental building block of DNA, responsible for carrying genetic information.
* **The synthetic analog** incorporates several modifications:
* **3-hydroxy-4-(hydroxymethyl)cyclopentyl group** replaces the deoxyribose sugar in thymidine. This alteration potentially alters the molecule's interactions with enzymes and other molecules involved in DNA replication and repair.
* **2-iodovinyl group** is added to the pyrimidine ring. This modification may enhance the compound's ability to bind to specific targets or affect its stability.
**Why it's important for research:**
* **Potential antiviral activity:** Modified nucleosides like this are often investigated for their potential to inhibit viral replication. They can interfere with the process by being incorporated into viral DNA, leading to dysfunctional viral proteins or stopping viral replication.
* **Drug development:** Modifying thymidine can create compounds that are better absorbed by the body, have improved pharmacokinetic properties, or overcome resistance to existing antiviral treatments.
* **Investigating DNA processes:** This compound can serve as a probe to study DNA-related processes like DNA replication, repair, and transcription. The modified structure can be used to track the molecule's fate and understand its interactions with cellular machinery.
**It's crucial to note:**
* This compound is **synthetic** and not found naturally.
* Its exact properties and potential applications need to be explored further through research and testing.
* The term 1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1H,3H)-pyrimidinedione is a long and complex name. Researchers may use abbreviations or simpler designations for easier reference.
**In conclusion, this modified thymidine analog holds potential in antiviral research and drug development. Understanding its specific interactions and effects through further investigation will shed light on its value as a therapeutic agent or a research tool.**
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1H,3H)-pyrimidinedione: RN & structure given in first source; RN refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 6439191 |
MeSH ID | M0131566 |
Synonyms (7)
Synonym |
2,4(1h,3h)-pyrimidinedione, 1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodoethenyl)-, (1alpha(e),3beta,4alpha)-(+-)- |
carbocyclic 2'-deoxy-5-(2-iodovinyl)uridine |
1-(3-hydroxy-4-(hydroxymethyl)cyclopentyl)-5-(2-iodovinyl)-2,4-(1h,3h)-pyrimidinedione |
carbocyclic 5-(2-iodovinyl)-2'-deoxyuridine |
91661-25-5 |
carbocyclic ivdu |
1-[(1s,3r,4s)-3-hydroxy-4-(hydroxymethyl)cyclopentyl]-5-[(e)-2-iodoethenyl]pyrimidine-2,4-dione |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 5 (83.33) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.35 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.29 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |